Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Reply letter to "Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab".

Dretler AW, Rouphael NG, Stephens DS.

Hum Vaccin Immunother. 2018 Jun 20:1-2. doi: 10.1080/21645515.2018.1491247. [Epub ahead of print] No abstract available.

PMID:
29923779
2.

Reply to "A refugee patient with meningococcal meningitis type B."

Dretler A, Rouphael N, Stephens D.

Hum Vaccin Immunother. 2018 May 24:1. doi: 10.1080/21645515.2018.1480243. [Epub ahead of print] No abstract available.

PMID:
29792550
3.

Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Sullivan NL, Reuter-Monslow MA, Sei J, Durr E, Davis CW, Chang C, McCausland M, Wieland A, Krah D, Rouphael N, Mehta AK, Mulligan MJ, Pulendran B, Ahmed R, Vora KA.

J Virol. 2018 Jun 29;92(14). pii: e00269-18. doi: 10.1128/JVI.00269-18. Print 2018 Jul 15.

PMID:
29743372
4.

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.

Dretler AW, Rouphael NG, Stephens DS.

Hum Vaccin Immunother. 2018 May 4;14(5):1146-1160. doi: 10.1080/21645515.2018.1451810. Epub 2018 May 9.

PMID:
29543582
5.

Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.

Levin MJ, Cai GY, Lee KS, Rouphael NG, Mehta AK, Canniff J, Mulligan MJ, Weinberg A.

J Infect Dis. 2018 Mar 13;217(7):1055-1059. doi: 10.1093/infdis/jix653.

PMID:
29409017
6.

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Rouphael N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH.

Vaccine. 2018 Jan 29;36(5):606-614. doi: 10.1016/j.vaccine.2017.12.061. Epub 2017 Dec 24.

PMID:
29279281
7.

Diagnostic Importance of Hyphae on Heart Valve Tissue in Histoplasma Endocarditis and Treatment With Isavuconazole.

Wiley Z, Woodworth MH, Jacob JT, Lockhart SR, Rouphael NG, Gullett JC, Guarner J, Workowski K.

Open Forum Infect Dis. 2017 Nov 24;4(4):ofx241. doi: 10.1093/ofid/ofx241. eCollection 2017 Fall.

8.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL; VRC 319; VRC 320 study teams.

Lancet. 2018 Feb 10;391(10120):552-562. doi: 10.1016/S0140-6736(17)33105-7. Epub 2017 Dec 5.

PMID:
29217376
9.

Microneedle patch for immunization of immunocompromised hosts.

Rouphael NG, Mulligan MJ.

Oncotarget. 2017 Oct 25;8(55):93311-93312. doi: 10.18632/oncotarget.22072. eCollection 2017 Nov 7. No abstract available.

10.

Innate, T-, and B-Cell Responses in Acute Human Zika Patients.

Lai L, Rouphael N, Xu Y, Natrajan MS, Beck A, Hart M, Feldhammer M, Feldpausch A, Hill C, Wu H, Fairley JK, Lankford-Turner P, Kasher N, Rago P, Hu YJ, Edupuganti S, Patel SM, Murray KO, Mulligan MJ; Emory Zika Patient Study Team .

Clin Infect Dis. 2018 Jan 6;66(1):1-10. doi: 10.1093/cid/cix732.

11.

Biphasic Zika Illness With Rash and Joint Pain.

Edupuganti S, Natrajan MS, Rouphael N, Lai L, Xu Y, Feldhammer M, Hill C, Patel SM, Johnson SJ, Bower M, Gorchakov R, Berry R, Murray KO, Mulligan MJ.

Open Forum Infect Dis. 2017 Jun 22;4(3):ofx133. doi: 10.1093/ofid/ofx133. eCollection 2017 Summer.

12.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB; DMID 08-0006 Tularemia Vaccine Study Group.

Vaccine. 2017 Aug 24;35(36):4730-4737. doi: 10.1016/j.vaccine.2017.07.024. Epub 2017 Jul 24.

13.

Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler.

Waggoner JJ, Rouphael N, Xu Y, Natrajan M, Lai L, Patel SM, Levit RD, Edupuganti S, Mulligan MJ.

Open Forum Infect Dis. 2017 May 18;4(2):ofx103. doi: 10.1093/ofid/ofx103. eCollection 2017 Spring.

14.

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group.

Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27.

PMID:
28666680
15.

Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker JA, Levin MJ.

J Immunol. 2017 Jul 15;199(2):604-612. doi: 10.4049/jimmunol.1700290. Epub 2017 Jun 12.

16.

Metabolic Phenotypes of Response to Vaccination in Humans.

Li S, Sullivan NL, Rouphael N, Yu T, Banton S, Maddur MS, McCausland M, Chiu C, Canniff J, Dubey S, Liu K, Tran V, Hagan T, Duraisingham S, Wieland A, Mehta AK, Whitaker JA, Subramaniam S, Jones DP, Sette A, Vora K, Weinberg A, Mulligan MJ, Nakaya HI, Levin M, Ahmed R, Pulendran B.

Cell. 2017 May 18;169(5):862-877.e17. doi: 10.1016/j.cell.2017.04.026. Epub 2017 May 11.

17.

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.

Jackson LA, Frey SE, El Sahly HM, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Rouphael N, Hill H, Goll JB.

Vaccine. 2017 Mar 23;35(13):1675-1682. doi: 10.1016/j.vaccine.2017.02.032. Epub 2017 Feb 27.

PMID:
28256358
18.

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.

Nasri H, Kabbani S, Bou Alwan M, Wang YF, Rebolledo PA, Kraft CS, Nguyen ML, Anderson AM, Rouphael N.

Open Forum Infect Dis. 2016 Apr 7;3(2):ofw076. doi: 10.1093/ofid/ofw076. eCollection 2016 Apr.

19.

Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.

Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael N, Frasca D, Gersten M, Mehta AK, Gaujoux R, Li GM, Gupta S, Ahmed R, Mulligan MJ, Shen-Orr S, Blomberg BB, Subramaniam S, Pulendran B.

Immunity. 2015 Dec 15;43(6):1186-98. doi: 10.1016/j.immuni.2015.11.012.

20.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, Sobieszczyk ME, Mayer KH, Swann E, Liao HX, Haynes BF, Graham BS, McElrath MJ; NIAID HIV Vaccine Trials Network.

J AIDS Clin Res. 2015 May;6(5). pii: 461. Epub 2015 May 23.

Supplemental Content

Loading ...
Support Center